FAQ

1. Chemical Structures and Properties

• LCZ696 Intermediate II (CAS No.: 1012341-48-8):
  • Chemical Name: (R,E)-5-([1,1′-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoic acid
  • Molecular Formula: C₂₃H₂₇NO₄
  • Molecular Weight: 381.46 g/mol
  • Function: Acts as a key intermediate in the synthesis of LCZ696, contributing to the formation of the active pharmaceutical ingredient (API).
• LCZ696 Intermediate N-3 (CAS No.: 1012341-50-2):
  • Chemical Name: (2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
  • Molecular Formula: C₂₃H₂₉NO₄
  • Molecular Weight: 383.48 g/mol
  • Function: Also serves as an intermediate in the synthesis of LCZ696, playing a distinct role in the chemical pathway leading to the final drug.

2. Structural Differences

• Stereochemistry and Configuration: The two intermediates differ in their stereochemistry and the configuration of certain functional groups. For example:
  • LCZ696 Intermediate II has an E-double bond (indicated by “(R,E)”) and a pent-2-enoic acid moiety.
  • LCZ696 Intermediate N-3 lacks the double bond and has a pentanoic acid structure, with specific (2R,4S) stereochemistry.
• Functional Groups: The presence or absence of the double bond and the arrangement of substituents (e.g., methyl, tert-butoxycarbonyl) distinguish these intermediates chemically.

3. Synthetic Roles

• LCZ696 Intermediate II: Likely involved in earlier stages of the synthetic route, contributing to the formation of key chiral centers or reactive sites that are essential for the final drug’s structure.
• LCZ696 Intermediate N-3: May serve as a later-stage intermediate, participating in reactions that finalize the drug’s molecular architecture or protect/deprotect functional groups during synthesis.

4. Physical and Chemical Properties

• Molecular Weight: LCZ696 Intermediate N-3 is slightly heavier (383.48 g/mol) compared to LCZ696 Intermediate II (381.46 g/mol) due to differences in molecular structure.
• Reactivity: The presence of the double bond in LCZ696 Intermediate II may influence its reactivity in coupling or cyclization reactions, whereas LCZ696 Intermediate N-3’s structure may favor different reaction pathways.

5. Applications and Uses

• Both intermediates are exclusively used in the pharmaceutical industry for the synthesis of LCZ696, a medication approved for treating heart failure.
• Their specific roles in the synthetic route depend on the chemical transformations required to build the complex structure of sacubitril/valsartan.

6. Safety and Handling

• As chemical intermediates, both compounds require careful handling under controlled conditions to prevent exposure and ensure safety in industrial or laboratory settings.
• Safety data sheets (SDS) for each intermediate would provide detailed information on hazards, protective measures, and emergency procedures.